to report our patients' outcomes of SNM in tertiary health centres in Turkey
We retrospectively analyzed 18 patients who underwent SNM for urinary or bowel dysfunction between 2017 and 2022 in our clinic. We excluded 2 patients due to non-effective responses after the test period. After local ethics committee approval was obtained from our institute (Number and date: 21-12.1T/14). Patient characteristics and demographic data including age, gender, indications to the SNM, age at diagnosis, and comorbidities were collected from our Hospital patients' record system. Urinary functions were evaluated by the ICIQ-SF questionnaire form. Patients' diagnosis, implantation duration, complications, and improvement of symptoms were recorded.
Study Type
OBSERVATIONAL
Enrollment
16
sacra neuromodulator implantation outcomes
Recovery of urinary or fecal incontinence
Significant decrease in urinary or fecal incontinence episode
Time frame: 1 year
increase in the score of ICIQ-SF questionnaire
improvement of quality of life and increase in the score of ICIQ-SF questionnaire
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.